Latest Vagus nerve Stories
HOUSTON, May 7, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the fourth quarter and fiscal year ended April 26, 2013, on Wednesday, June 5, 2013, before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time). Fourth Quarter and Fiscal Year 2013 Results Webcast and Conference Call InstructionsThe conference...
HOUSTON, April 4, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today provided an update on its recent submission to the Centers for Medicare & Medicaid Services ("CMS") seeking reimbursement coverage for the treatment-resistant depression ("TRD") indication for the VNS Therapy(®) System. As previously announced, the company submitted a request to CMS for reconsideration of coverage for VNS Therapy for TRD and expected to receive a formal acknowledgment from CMS accepting...
redOrbit Staff & Wire Reports - Your Universe Online A team of UK scientists has developed an implantable microchip which they claim is capable of suppressing appetite, potentially making it a powerful new weapon in the fight against obesity. The microchips were designed by Imperial College London professors Chris Toumazou and Sir Stephen Bloom, and according to FrenchTribune.com, they will soon be tested in a series of animal trials which could determine whether or not they are a...
MORRIS PLAINS, N.J., Feb. 19, 2013 /PRNewswire/ -- ElectroCore(®), a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious medical conditions including primary headaches, announced today that its GammaCore(®) therapy has been approved for commercial sale by the Therapeutic Goods Administration in Australia and the National Institute of Surveillance of Medicine and Foods in the Ministry of Health in Colombia. GammaCore's...
HOUSTON, Feb. 13, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the following conferences. Dan Moore, Cyberonics' President & Chief Executive Officer, will participate in the neuromodulation panel discussion at the Citi 2013 Global Healthcare Conference in New York on Wednesday, February 27, 2013 at 11:05 AM Eastern Time. This panel discussion will not...
HOUSTON, Texas, Feb. 6, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that the company will report financial results for the third quarter ended January 25, 2013, of its fiscal year ending April 26, 2013, on Friday, February 22, 2013, before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time). Fiscal Year 2013 Third Quarter Results Webcast and...
HOUSTON, Feb. 4, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that the lawsuit filed by former employee Andrew Hagerty in federal district court in Massachusetts was voluntarily dismissed without prejudice by Mr. Hagerty on February 1, 2013. The company has asserted that, under the terms of his employment, Mr. Hagerty's claims are subject to binding arbitration. Mr. Hagerty has the right to re-file the lawsuit or to pursue a resolution through binding...
MORRIS PLAINS, N.J., Jan. 9, 2013 /PRNewswire/ -- ElectroCore®, a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious neurological conditions and bronchoconstriction, announced today that Eric Liebler, co-founder and former President of Nautilus Neurosciences, Inc., has joined ElectroCore as VP, Scientific, Medical and Governmental Affairs. Mr. Liebler brings more than 20 years of neurological industry and association...
HOUSTON, Jan. 9, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that Bruce H. KenKnight, Ph.D., joined the company as its Vice President, Emerging Therapies, effective on January 1, 2013. Dr. KenKnight will lead all of the company's emerging therapies programs, including the current clinical evaluation of Autonomic Regulation Therapy, an emerging therapy for treatment of chronic heart failure that incorporates Cyberonics' extensive experience delivering vagus...
MORRIS PLAINS, N.J., Jan. 4, 2013 /PRNewswire/ -- ElectroCore®, a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious headache conditions and bronchoconstriction, announced today that Reese Terry, co-founder and former CEO of Cyberonics, Inc., has joined its Board of Directors. Mr. Terry brings more than 25 years of relevant medical device industry experience to ElectroCore. He co-founded Cyberonics in 1987 to develop,...
